4 Stocks With More Than 20% Price Increases on Thursday

Markets soar on US-China trade talk optimism

Author's Avatar
Oct 10, 2019
Article's Main Image

In light of markets soaring on trade optimism between the U.S. and China, four stocks that increased more than 20% on Thursday morning according to the All-in-One Screener were Ra Pharmaceuticals Inc. (RARX, Financial), OncoSec Medical Inc. (ONCS, Financial), Bed Bath & Beyond Inc. (BBBY, Financial) and ProPetro Holding Corp. (PUMP, Financial).

Dow rockets as U.S.-China trade talks commence

The Dow Jones Industrial Average reached an intraday high of 26,603.31, up 257.30 points from Wednesday’s close of 26,346.01 on the heels of President Trump’s announcement that he and Chinese Vice Premier Liu He will meet on Friday for a “big day of negotiations.” Shares of Caterpillar Inc. (CAT, Financial) jumped over 2% on the news.

c338b6d3020f717f151cdb2dbbbde7af.png

According to the All-in-One Screener, a GuruFocus Premium feature, four stocks with a current price of at least $1 have increased over 20% from the previous close.

Ra Pharmaceuticals

Shares of Ra Pharmaceuticals traded at $45.58, up 100.82% from the previous close of $22.70.

044741f77993956420c7e9643be9adf1.png

The Cambridge, Massachusetts-based clinical-stage biotech company discovers and develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. According to GuruFocus, the company has a cash-to-debt ratio of 35.74, which outperforms 64.13% of global competitors.

OncoSec Medical

Shares of OncoSec Medical traded at $2.16, up 32.01% from its previous close of $1.64.

9d0d443a57a3c88f204be5b5b15221d7.png

The San Diego-based company designs, develops and commercializes gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response to the treatment of cancer. According to GuruFocus, OncoSec’s cash-to-debt ratio of 140.1 outperforms 72.18% of global competitors while its debt-to-equity ratio of 0.01 outperforms 87.76% of global biotech companies.

Bed Bath & Beyond

Shares of Bed Bath & Beyond traded at $12.10, up 21.73% from its previous close of $9.94. The stock rocketed on the heels of the Union, New Jersey-based home furnishings retailer announcing Target Corp. (TGT, Financial) Executive Vice President and Chief Marketing Officer Mark Tritton as its new CEO, effective Nov. 4.

823300c50d9730047c8702a4c1ef4bc9.png

Gurus cheering on Bed Bath & Beyond’s new CEO announcement include Jim Simons (Trades, Portfolio)’ Renaissance Technologies, Ray Dalio (Trades, Portfolio)’s Bridgewater Associates and Joel Greenblatt (Trades, Portfolio).

ProPetro

Shares of ProPetro traded at $9.68, pumping 22.61% higher than its previous close of $7.90.

7b45985647fb875b4ed87b57d554aab0.png

The Midland, Texas-based company provides hydraulic fracturing and other complementary services to upstream oil and gas companies. GuruFocus lists several positive investing signs for ProPetro, including a strong Piotroski F-score of 7 and operating margins that outperform 85.38% of global competitors.

Disclosure: No positions.

Read more here:

Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.